PerkinElmer posted revenue and operating income increases in its second quarter 2021 (end-July 4).
For the quarter, the company reported revenue in its Discovery and Analytical Solutions segment of $513 million, compared to $391 million for the same period in 2020. It posted operating income from continuing operations for the segment of $64 million, compared to $39 million for the second quarter of last year, and operating income of $101 million, compared to $57 million in the same period in 2020.
In other PerkinElmer news, the company announced that it will acquire antibody and research reagent manufacturer BioLegend for $5.25 billion.